MeiraGTx Holdings (MGTX) said Tuesday that data from a study of its experimental Parkinson's disease treatment, AAV-GAD, showed a statistically significant improvement in motor examination score in the high-dose group compared with no significant change in the sham or low-dose groups.
The drug also significantly improved the disease-specific, patient-reported quality of life measures in both the high and low-dose groups, with no substantial change in the sham group.
AAV-GAD was safe and well tolerated, with no serious adverse events reported.
The company plans to use the study's data for discussions with regulators in the US, Europe, and Japan to initiate a global Phase 3 study.
MeiraGTx shares jumped more than 12% in premarket trading.
Price: 5.2100, Change: +0.57, Percent Change: +12.28
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。